Free shipping on all orders over $ 500

Lersivirine

Cat. No. M3743
Lersivirine Structure
Synonym:

UK-453061

Size Price Availability Quantity
5mg USD 115 In stock
10mg USD 190 In stock
50mg USD 660 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

Lersivirine is a potent enzyme inducer in rodents capable of inducing a number of hepatic enzymes including those involved in its own metabolism. Preclinically lersivirine has been associated with hepatocellular hypertrophy and thyroid gland follicular cell hypertrophy in rats, mice, and dogs. Lersivirine has therapeutic potential for HIV-infected individuals with viral strains resistant against first-line NNRTIs. However, no large, well-powered studies have been conducted so far, which assess noninferiority against established antiretroviral agents. Lersivirine 750 mg and 1,000 mg qd was associated with lower rates of viral suppression at week 24 and week 48 versus etravirine in patients with prior NNRTI use and evidence of NNRTI resistance. No new safety signals were detected.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 310.35
Formula C17H18N4O2
CAS Number 473921-12-9
Purity >99%
Solubility DMSO
Storage at -20°C
References

Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.
DeJesus E, et al. HIV Clin Trials. 2014 Sep-Oct;15(5):209-17. PMID: 25350959.

Effects of Lersivirine on Canine and Rodent Thyroid Function.
Houle CD, et al. Toxicol Pathol. 2013 Oct 16;42(5):897-912. PMID: 24135463.

Lersivirine - a new drug for HIV infection therapy.
Platten M, et al. Expert Opin Investig Drugs. 2013 Dec;22(12):1687-94. PMID: 24128277.

Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers.
Vourvahis M, et al. Drug Alcohol Depend. 2012 Nov 1;126(1-2):183-8. PMID: 22682979.

Related HIV Protease Products
Darunavir

Darunavir is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.

Saquinavir Mesylate

Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy.

Saquinavir

Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy.

Atazanavir

Atazanavir is an azapeptide and HIV-protease inhibitor that is used in the treatment of HIV infections and AIDS in combination with other anti-HIV agents.

Dolutegravir sodium

Dolutegravir sodium is a potent, second generation HIV integrase inhibitor (IC₅₀ = 2.7 nM) that displays potent antiviral activity.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Lersivirine, UK-453061 supplier, HIV Protease, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.